ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) shares saw an uptick in trading volume on Wednesday . 567,312 shares traded hands during mid-day trading, an increase of 6% from the previous session’s volume of 533,951 shares.The stock last traded at $10.76 and had previously closed at $10.75.
Analyst Upgrades and Downgrades
Several brokerages have issued reports on ORIC. Oppenheimer lowered their target price on shares of ORIC Pharmaceuticals from $17.00 to $15.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 13th. HC Wainwright reaffirmed a “buy” rating and set a $21.00 price objective on shares of ORIC Pharmaceuticals in a research note on Wednesday, September 18th. Stifel Nicolaus began coverage on shares of ORIC Pharmaceuticals in a research note on Friday, September 6th. They issued a “buy” rating and a $20.00 target price on the stock. Wedbush restated an “outperform” rating and set a $20.00 target price on shares of ORIC Pharmaceuticals in a report on Tuesday, September 10th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ORIC Pharmaceuticals in a report on Monday. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, ORIC Pharmaceuticals has a consensus rating of “Buy” and an average target price of $18.00.
Read Our Latest Stock Analysis on ORIC
ORIC Pharmaceuticals Stock Down 3.1 %
ORIC Pharmaceuticals (NASDAQ:ORIC – Get Free Report) last posted its earnings results on Monday, August 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.03). As a group, sell-side analysts forecast that ORIC Pharmaceuticals, Inc. will post -1.78 earnings per share for the current year.
Institutional Trading of ORIC Pharmaceuticals
A number of hedge funds and other institutional investors have recently modified their holdings of ORIC. NEA Management Company LLC purchased a new position in ORIC Pharmaceuticals during the first quarter worth about $20,625,000. Price T Rowe Associates Inc. MD boosted its position in shares of ORIC Pharmaceuticals by 140.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,566,736 shares of the company’s stock worth $21,543,000 after purchasing an additional 915,175 shares during the period. Vanguard Group Inc. increased its holdings in ORIC Pharmaceuticals by 27.9% in the 1st quarter. Vanguard Group Inc. now owns 2,882,055 shares of the company’s stock valued at $39,628,000 after purchasing an additional 629,536 shares during the last quarter. Millennium Management LLC raised its position in ORIC Pharmaceuticals by 297.4% in the second quarter. Millennium Management LLC now owns 782,299 shares of the company’s stock valued at $5,531,000 after purchasing an additional 585,447 shares during the period. Finally, First Turn Management LLC lifted its stake in ORIC Pharmaceuticals by 38.1% during the second quarter. First Turn Management LLC now owns 1,515,960 shares of the company’s stock worth $10,718,000 after purchasing an additional 418,389 shares in the last quarter. 95.05% of the stock is owned by institutional investors and hedge funds.
ORIC Pharmaceuticals Company Profile
ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.
Read More
- Five stocks we like better than ORIC Pharmaceuticals
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Analyst Think There’s Still Time to Get in on Edgewise, Up 332%
- What Are Some of the Best Large-Cap Stocks to Buy?
- 3 Stocks Raising Dividends 4X Higher Than Inflation
- What Are Dividends? Buy the Best Dividend Stocks
- Palantir Stock Joins the S&P 500; Is It Time to Buy?
Receive News & Ratings for ORIC Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ORIC Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.